Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 101 clinical trials
Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

participants with non-squamous NSCLC without a known sensitizing epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or receptor tyrosine kinase-1 (ROS-1) mutation, BRAF V600E mutation

  • 0 views
  • 26 Apr, 2021
  • 31 locations
A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC MK-7339-008/KEYLYNK-008)

The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, vs. pembrolizumab plus maintenance olaparib placebo for the treatment of squamous NSCLC. The study's 2 primary

  • 119 views
  • 12 May, 2021
  • 202 locations
Platinum-Based Chemotherapy With/Without INCMGA00012 an Anti-PD-1 Antibody in Non-Small Cell Lung Cancer

The purpose of this study is to assess the efficacy and safety of platinum-based chemotherapy with or without INCMGA00012 in participants with metastatic squamous and nonsquamous non-small cell lung cancer (NSCLC).

  • 69 views
  • 02 Apr, 2021
  • 61 locations
A Study to Test Different Doses of BI 836880 Combined With BI 754091 in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours

This study has 2 parts. The first part is open to adults with advanced non-small cell lung cancer. The second part is open also to adults with other types of advanced cancer of the lung, brain, skin, and liver. The participants get a combination of two medicines called BI 836880 …

alopecia
antineoplastic agents
immunostimulants
advanced cancer
lung cancer
  • 17 views
  • 12 May, 2021
  • 63 locations
A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer

etrumadenant (AB928) in combination with carboplatin and pemetrexed, with or without an anti-PD-1 antibody (pembrolizumab or zimberelimab), in participants with non-squamous Non-Small Cell Lung Cancer (NSCLC

carboplatin
measurable disease
growth factor
epidermal growth factor
non-squamous non-small cell lung cancer
  • 74 views
  • 30 Jan, 2021
  • 79 locations
A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

line Stage IIIB/IIIC or IV non-squamous NSCLC. Participants will be randomized in a 1:1:1 ratio to Arm A (HLX10+HLX04+Carboplatin+Pemetrexed), Arm B (HLX10+Carboplatin+Pemetrexed), or Arm C

carboplatin
measurable disease
avastin
lung cancer
cancer
  • 0 views
  • 24 Jan, 2021
  • 1 location
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

-positive non-squamous non-small cell lung cancer (NSCLC) that has spread to other parts of the body. Participants who are assigned to the standard treatment and discontinue due to progressive disease have

carboplatin
progressive disease
non-squamous non-small cell lung cancer
RET
lung carcinoma
  • 16 views
  • 12 May, 2021
  • 316 locations
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

induction with pembrolizumab, pemetrexed and carboplatin followed by pembrolizumab and pemetrexed maintenance in treating patients with stage IV non-squamous non-small cell lung cancer. Immunotherapy with

brain metastases
anticonvulsants
aptt
squamous non-small cell lung carcinoma
HIV Infection
  • 206 views
  • 09 May, 2021
  • 819 locations
Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer

This randomized phase 2 open-label study will evaluate the safety and efficacy of zimberelimab (AB122) monotherapy, domvanalimab (AB154) in combination with zimberelimab, and domvanalimab in combination with zimberelimab and etrumadenant (AB928) in front-line, PD-L1 positive, locally advanced or metastatic non-small cell lung cancer.

measurable disease
growth factor
epidermal growth factor
lung cancer
lung carcinoma
  • 61 views
  • 30 Apr, 2021
  • 131 locations
Study to Evaluate Monotherapy Compared to Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer

This Randomized Phase 3 Open-label Study will Evaluate the Efficacy of Zimberelimab (AB122) Monotherapy Compared to Standard Chemotherapy or Zimberelimab Combined with AB154 in Front-Line, PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

  • 0 views
  • 28 Apr, 2021
  • 3 locations